Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Pembrolizumab/Axitinib Improves Outcomes in Japanese mRCC Subgroup

November 30th 2021

The combination of pembrolizumab and axitinib demonstrated comparable activity and safety vs sunitinib in Japanese patients vs the global population of patients with newly diagnosed metastatic renal cell carcinoma enrolled in the phase 3 KEYNOTE-426 trial.

CG0070 Plus Pembrolizumab Shows Early Tolerability and Activity in BCG-Unresponsive Non–Muscle Invasive Bladder Cancer

November 29th 2021

The combination of CG0070 and pembrolizumab was well tolerated and demonstrated early signals of activity in patients with Bacille Calmette-Guérin-unresponsive non–muscle invasive bladder cancer.

Investigators Set Their Sets on Novel Targets in Genitourinary Malignancies

November 27th 2021

Manojkumar Bupathi, MD, MS, shares the main highlights from the meeting, which centered on frontline, second, and later-line treatment of metastatic urothelial carcinoma and metastatic renal cell carcinoma.

Dr. Saif on Recommendations for Germline Testing in Pancreatic Cancer

November 23rd 2021

Wasif M. Saif, MD, MBBS, discusses recommendations for germline testing in patients with pancreatic cancer.

Dr. Vaishampayan on the Future Directions for Second-Line Treatment in Urothelial Cancer

November 23rd 2021

Ulka Nitin Vaishampayan, MBBS, discusses future directions for second-line treatment in urothelial cancer.

Dr. Palmbos on Remaining Questions in Metastatic Urothelial Carcinoma

November 22nd 2021

Phillip L. Palmbos, MD, PhD, discusses remaining questions in metastatic urothelial carcinoma.

Dr. Galsky on Developments in SOC Metastatic Urothelial Cancer Treatment

November 22nd 2021

Matthew Galsky, MD, discusses key developments in the standard-of-care treatment of patients with metastatic or advanced urothelial cancer.

Dr. Choueiri on the FDA Approval of Adjuvant Pembrolizumab in RCC

November 19th 2021

Toni K. Choueiri, MD, discusses the FDA approval of adjuvant pembrolizumab in renal cell carcinoma.

Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With Cancer

November 19th 2021

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

Dr. Ramnaraign on Current Treatment Guidelines for First-Line Metastatic RCC

November 18th 2021

Brian Ramnaraign, MD, discusses current first-line treatment guidelines for patients with metastatic renal cell carcinoma. 

FDA Approves Adjuvant Pembrolizumab for RCC

November 18th 2021

The FDA has approved pembrolizumab for the adjuvant treatment of patients with renal cell carcinoma who are at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

Subsequent-line Treatment in Advanced RCC Leaves Room for Personalization

November 17th 2021

For patients with advanced clear cell renal cell carcinoma, it will be of utmost importance to recognize the vari­ation in response and type of progression with first-line therapy, the patient’s charac­teristics and motivations, and the promise of new agents and combinations.

Dr. Bupathi on First-Line Treatment Options for Clear Cell RCC

November 16th 2021

Manojkumar Bupathi, MD, MS, discusses the improvement in first-line treatment options for patients with clear cell renal cell carcinoma.

Patients with RCC, Melanoma Taking ICIs Can Safely Receive COVID-19 Vaccination

November 15th 2021

The COVID-19 vaccine was safe and well tolerated in patients who received immune checkpoint inhibitors for renal cell carcinoma or melanoma.

Dr. Yu on the Utility of Enfortumab Vedotin in Metastatic Urothelial Cancer

November 12th 2021

Evan Y. Yu, MD, discusses the utility of enfortumab vedotin-ejfv in patients with locally advanced or metastatic urothelial cancer. 

Dr. Grivas on Attempts to Improve Upon Chemotherapy in Urothelial Cancer

November 12th 2021

Petros Grivas, MD, PhD, discusses attempts to improve upon chemotherapy as a therapeutic strategy in urothelial cancer.

Investigators Set Their Sights on Optimizing Sequencing With Novel Therapies in GU Cancers

November 12th 2021

Treatment selection and sequencing in genitourinary cancers, such as metastatic bladder cancer and metastatic renal cell carcinoma, have become more complicated and require nuanced decision making.

Dr. Michalski on the Goals ASTRO in Radiation Oncology

November 11th 2021

Jeff Michalski, MD, MBA, FASTRO, discusses the goals of the American Society for Radiation Oncology in radiation oncology.

Dr. Yentz on Unmet Needs in Metastatic RCC

November 11th 2021

Sarah Elizabeth Yentz, MD, discusses unmet needs in metastatic renal cell carcinoma.

Dr. Palmbos on the Role of Chemoimmunotherapy in Bladder Cancer

November 11th 2021

Phillip Palmbos, MD, PhD, discusses the role of chemoimmunotherapy in patients with bladder cancer.